Variables associated with use of symptomatic medication during a headache attack in individuals with tension-type headache: a European study.


Journal

BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555

Informations de publication

Date de publication:
01 Feb 2020
Historique:
received: 16 07 2019
accepted: 21 01 2020
entrez: 3 2 2020
pubmed: 3 2 2020
medline: 4 6 2020
Statut: epublish

Résumé

Pharmacological treatment of patients with tension-type headache (TTH) includes symptomatic (acute) and prophylactic (preventive) medication. No previous study has investigated variables associated to symptomatic medication intake in TTH. Our aim was to assess the association of clinical, psychological and neurophysiological outcomes with the use and timing of the use of symptomatic medication in TTH. A longitudinal observational study was conducted. One hundred and sixty-eight (n = 168) patients with TTH participated. Pain features of the headache (intensity, frequency, duration), burden of headache (Headache Disability Inventory), sleep quality (Pittsburgh Sleep Quality Index), anxiety/depression (Hospital Anxiety and Depression Scale), trait/state anxiety levels (State-Trait Anxiety Inventory), and bilateral pressure pain thresholds on the temporalis, C5-C6 joint, second metacarpal and tibialis anterior were assessed. Symptomatic medication intake was also collected for a 6-months follow-up period. Differences between patients using or not using symptomatic medication, depending on self-perceived effectiveness, and time (early during an attack, i.e., the first 5 min, or when headache attack is intense) when the symptomatic medication was taken were calculated. One hundred and thirty-six (n = 136, 80%) reported symptomatic medication intake for headache (73% NSAIDs). Sixteen (12%) reported no pain relief, 81 (59%) experienced moderate relief and 39 (29%) total pain relief. Fifty-eight (43%) took 'early medication' whereas 78 (57%) took 'late medication'. Patients taking symptomatic medication in general showed lower headache frequency and lower depressive levels than those patients not taking medication. Symptomatic medication was more effective in patients with lower headache history, frequency, and duration, and lower emotional burden. No differences in pressure pain sensitivity were found depending on the self-perceived effectiveness of medication. Patients taking 'late symptomatic' medication exhibited more widespread pressure pain sensitivity than those taking 'early medication'. This study found that the effectiveness of symptomatic medication was associated with better headache parameters (history, frequency, or duration) and lower emotional burden. Further, consuming early symptomatic medication at the beginning of a headache attack (the first 5 min) could limit widespread pressure pain sensitivity.

Sections du résumé

BACKGROUND BACKGROUND
Pharmacological treatment of patients with tension-type headache (TTH) includes symptomatic (acute) and prophylactic (preventive) medication. No previous study has investigated variables associated to symptomatic medication intake in TTH. Our aim was to assess the association of clinical, psychological and neurophysiological outcomes with the use and timing of the use of symptomatic medication in TTH.
METHODS METHODS
A longitudinal observational study was conducted. One hundred and sixty-eight (n = 168) patients with TTH participated. Pain features of the headache (intensity, frequency, duration), burden of headache (Headache Disability Inventory), sleep quality (Pittsburgh Sleep Quality Index), anxiety/depression (Hospital Anxiety and Depression Scale), trait/state anxiety levels (State-Trait Anxiety Inventory), and bilateral pressure pain thresholds on the temporalis, C5-C6 joint, second metacarpal and tibialis anterior were assessed. Symptomatic medication intake was also collected for a 6-months follow-up period. Differences between patients using or not using symptomatic medication, depending on self-perceived effectiveness, and time (early during an attack, i.e., the first 5 min, or when headache attack is intense) when the symptomatic medication was taken were calculated.
RESULTS RESULTS
One hundred and thirty-six (n = 136, 80%) reported symptomatic medication intake for headache (73% NSAIDs). Sixteen (12%) reported no pain relief, 81 (59%) experienced moderate relief and 39 (29%) total pain relief. Fifty-eight (43%) took 'early medication' whereas 78 (57%) took 'late medication'. Patients taking symptomatic medication in general showed lower headache frequency and lower depressive levels than those patients not taking medication. Symptomatic medication was more effective in patients with lower headache history, frequency, and duration, and lower emotional burden. No differences in pressure pain sensitivity were found depending on the self-perceived effectiveness of medication. Patients taking 'late symptomatic' medication exhibited more widespread pressure pain sensitivity than those taking 'early medication'.
CONCLUSIONS CONCLUSIONS
This study found that the effectiveness of symptomatic medication was associated with better headache parameters (history, frequency, or duration) and lower emotional burden. Further, consuming early symptomatic medication at the beginning of a headache attack (the first 5 min) could limit widespread pressure pain sensitivity.

Identifiants

pubmed: 32007103
doi: 10.1186/s12883-020-1624-8
pii: 10.1186/s12883-020-1624-8
pmc: PMC6995039
doi:

Substances chimiques

Analgesics 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

43

Références

Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
Lancet. 2016 Oct 8;388(10053):1545-1602
pubmed: 27733282
J Pain. 2005 Jun;6(6):348-55
pubmed: 15943956
Neurol Sci. 2013 May;34 Suppl 1:S137-8
pubmed: 23695063
J Headache Pain. 2014 May 21;15:31
pubmed: 24884549
Cephalalgia. 2011 Nov;31(15):1549-60
pubmed: 22019575
Pain. 1999 Nov;83(2):157-62
pubmed: 10534586
Cochrane Database Syst Rev. 2016 Sep 22;9:CD012190
pubmed: 27654948
Zhonghua Yi Xue Za Zhi (Taipei). 1999 Nov;62(11):749-55
pubmed: 10575802
Int J Clin Pract Suppl. 2015 May;(182):3-7
pubmed: 25907016
Neurology. 1994 May;44(5):837-42
pubmed: 8190284
Pain Pract. 2017 Mar;17(3):392-401
pubmed: 27207273
Eur J Neurol. 2010 Nov;17(11):1318-25
pubmed: 20482606
J Orthop Sports Phys Ther. 2011 Sep;41(9):644-50
pubmed: 21885906
Clin Ther. 2007;29 Suppl:2580-8
pubmed: 18164923
Pain. 2006 Jul;123(1-2):19-27
pubmed: 16630694
Cephalalgia. 2010 Oct;30(10):1250-67
pubmed: 20873360
Cephalalgia. 2010 Mar;30(3):285-95
pubmed: 19614706
Clin J Pain. 2019 Apr;35(4):315-320
pubmed: 30640741
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Cephalalgia. 2010 Mar;30(3):321-8
pubmed: 19614708
J Headache Pain. 2014 Sep 26;15:64
pubmed: 25260261
Cephalalgia. 2010 Jan;30(1):1-16
pubmed: 19614696
Int J Epidemiol. 2014 Apr;43(2):476-93
pubmed: 24648481
Eur J Neurol. 2003 Mar;10(2):147-52
pubmed: 12603289
J Psychosom Res. 1998 Jul;45(1):5-13
pubmed: 9720850
J Headache Pain. 2016;17:59
pubmed: 27245683
Cephalalgia. 2013 Jul;33(9):629-808
pubmed: 23771276
Cochrane Database Syst Rev. 2017 Jan 13;1:CD011888
pubmed: 28084009
Cochrane Database Syst Rev. 2015 Jul 31;(7):CD011474
pubmed: 26230487
Curr Rheumatol Rev. 2016;12(2):127-39
pubmed: 26717946
Cochrane Database Syst Rev. 2016 Jun 16;(6):CD011889
pubmed: 27306653
Headache. 1995 Oct;35(9):534-9
pubmed: 8530277
Inflammopharmacology. 2013 Jun;21(3):201-32
pubmed: 23719833

Auteurs

César Fernández-de-Las-Peñas (C)

Department Physical Therapy, Occupational Therapy, Rehabilitation, and Physical Medicine, University Rey Juan Carlos, Alcorcón, Spain. cesarfdlp@yahoo.es.
Department of Health Science and Technology, Faculty of Medicine, Center for Sensory-Motor Interaction (SMI), Aalborg University, Aalborg, Denmark. cesarfdlp@yahoo.es.
Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Avenida de Atenas s/n28922 Alcorcón, Madrid, Spain. cesarfdlp@yahoo.es.

Maria Palacios-Ceña (M)

Department Physical Therapy, Occupational Therapy, Rehabilitation, and Physical Medicine, University Rey Juan Carlos, Alcorcón, Spain.
Department of Health Science and Technology, Faculty of Medicine, Center for Sensory-Motor Interaction (SMI), Aalborg University, Aalborg, Denmark.

Matteo Castaldo (M)

Department of Health Science and Technology, Faculty of Medicine, Center for Sensory-Motor Interaction (SMI), Aalborg University, Aalborg, Denmark.
Master in Sport Physiotherapy, University of Siena, Siena, Italy.
Poliambulatorio Fisiocenter, Collecchio (Parma), Collecchio, Italy.

Kelun Wang (K)

Department of Health Science and Technology, Faculty of Medicine, Center for Sensory-Motor Interaction (SMI), Aalborg University, Aalborg, Denmark.

Ángel Guerrero-Peral (Á)

Headache Unit, Hospital Universitario de Valladolid, Valladolid, Spain.

Antonella Catena (A)

Master in Sport Physiotherapy, University of Siena, Siena, Italy.

Lars Arendt-Nielsen (L)

Department of Health Science and Technology, Faculty of Medicine, Center for Sensory-Motor Interaction (SMI), Aalborg University, Aalborg, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH